GROUPE FRANCOPHONE DES MYELODYSPLASIES

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2018-04-19
Last Posted Date
2024-04-19
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
68
Registration Number
NCT03503409
Locations
🇫🇷

CHU côte de Nacre, Caen, France

🇫🇷

CH Angers, Angers, France

🇫🇷

Centre Hospitalier de la Côte Basque, Bayonne, France

and more 35 locations

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

First Posted Date
2018-03-06
Last Posted Date
2018-11-15
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
40
Registration Number
NCT03454984
Locations
🇫🇷

CHU d'Angers, Angers, France

🇫🇷

Hôpital St Louis, Paris, France

🇫🇷

CHU Estaing, Clermont-Ferrand, France

and more 9 locations

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Phase 3
Conditions
Interventions
First Posted Date
2017-07-21
Last Posted Date
2020-12-02
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
124
Registration Number
NCT03223961
Locations
🇫🇷

Chu Amiens, Amiens, France

🇫🇷

CH Avignon, Avignon, France

🇫🇷

CH Angers, Angers, France

and more 36 locations

A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders

Phase 2
Completed
Conditions
Interventions
First Posted Date
2016-12-07
Last Posted Date
2022-10-04
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
30
Registration Number
NCT02985190
Locations
🇫🇷

Hôpital Avicenne, Bobigny, France

🇫🇷

CHU Amiens, Amiens cedex 01, France

🇫🇷

CHR d'Orléans, Orléans, France

and more 56 locations

French Registry of First-line Treatment of Acute Promyelocytic Leukemia

First Posted Date
2016-10-19
Last Posted Date
2016-10-19
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
400
Registration Number
NCT02938858
Locations
🇫🇷

CHU Estaing, Clermont-Ferrand, France

🇫🇷

Centre Hospitalier V. Dupouy, Argenteuil, France

🇫🇷

Centre Hospitalier d'Aix en Provence, Aix en Provence, France

and more 24 locations

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2016-05-02
Last Posted Date
2024-08-02
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
79
Registration Number
NCT02757989
Locations
🇫🇷

Centre hospitalier Victor Dupouy, Argenteuil, France

🇫🇷

CHSF Gilles de Corbeil, Corbeil-Essonnes, France

🇫🇷

CHU d'Angers, Angers, France

and more 34 locations

Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-04-29
Last Posted Date
2015-04-29
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
50
Registration Number
NCT02428686
Locations
🇫🇷

Hôpital Américain de Paris, Neuilly Sur Seine, France

🇫🇷

CHU de Reims, Reims, France

🇫🇷

Hopital de la Cote Basque, Bayonne, France

and more 28 locations

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-12-23
Last Posted Date
2021-04-20
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
30
Registration Number
NCT02323178
Locations
🇫🇷

CHU d'Angers, Angers, France

🇫🇷

Hôpital privé Sévigné, Cesson-Sévigné, France

🇫🇷

Centre Hospitalier de Meaux, Meaux, France

and more 23 locations

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-12-23
Last Posted Date
2018-12-06
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
23
Registration Number
NCT02323139
Locations
🇫🇷

CHU d'Amiens, Amiens, France

🇫🇷

IPC-Unité d'Hématologie 3, Marseille, France

🇫🇷

Centre Hospitalier de Meaux, Meaux, France

and more 21 locations

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-08-12
Last Posted Date
2021-11-19
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
170
Registration Number
NCT02214407
Locations
🇫🇷

Hôpital Avicenne, Bobigny, France

🇫🇷

CHU La Réunion - Site nord, Saint-Denis, La Réunion, France

🇫🇷

Chu Amiens, Amiens, France

and more 42 locations
© Copyright 2024. All Rights Reserved by MedPath